Cardiometabolic and Lipids Strategies for Primary Care-Non alcoholic Fatty Liver guideline

Video Transcription

Video Summary

The video features three speakers discussing non-alcoholic fatty liver disease (NAFLD) and its complications. The first speaker, Dr. Scott Isaacs, discusses the understanding of the epidemic of fatty liver disease. He provides an overview of the different types of fatty liver disease and the progression of NAFLD to more severe complications such as non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. He also discusses the global prevalence of NAFLD and its association with cardiovascular disease. Dr. Romina Lomonako, the second speaker, covers diagnostic tools and complications of fatty liver disease. She discusses the importance of screening high-risk individuals, such as those with type 2 diabetes, obesity, and elevated liver enzymes. She also explains various non-invasive biochemical diagnostic tools and non-invasive imaging tests for the evaluation of NASH and liver fibrosis. The final speaker, Dr. Cusi, talks about current and future treatments of fatty liver disease. He highlights the role of lifestyle changes, including diet and exercise, and the use of specific medications such as pioglitazone and GLP-1 receptor agonists. He also mentions potential future treatments being developed, including PPR agonists and GLP-1 glucagon receptor agonists.<br /><br />Overall, the video provides information on the challenges and management strategies for NAFLD, including the importance of early detection, lifestyle changes, and pharmacological interventions. The speakers emphasize the need for regular screening of high-risk individuals and the role of different diagnostic tools and medications in the management of fatty liver disease complications.

Keywords

non-alcoholic fatty liver disease

NAFLD

complications

non-alcoholic steatohepatitis

NASH

fibrosis

cirrhosis

cardiovascular disease

diagnostic tools

screening

lifestyle changes